Cellebrite DI Ltd. Ordinary Shares

Cellebrite DI Ltd. Ordinary Shares Q3 2026 Earnings Recap

CLBT Q3 2026 Published November 14, 2026

Get alerts when CLBT reports next quarter

Set up alerts — free

Cellebrite shares fell 9.2% after earnings, despite Q3 results above company guidance. The transcript points to lingering concern about the outlook: management described the U.S. go-to-market response as improved after Q2 and said updated financial guidance would follow, but the supplied remarks do not include the revised outlook.

Earnings Per Share Beat
$0.11 vs $0.09 est.
+17.0% surprise
Revenue Beat
149022000 vs 145826600 est.
+2.2% surprise

Market Reaction

Post-Earnings -9.21%

See CLBT alongside your other holdings

Add to your portfolio — free

Key Takeaways

  • CEO said Q3 ARR, revenue and adjusted EBITDA finished above company guidance; international performance and a reaccelerating U.S. federal business drove top-line growth.
  • EMEA grew 22% and Asia-Pacific 31%. Two large U.S. federal customers each increased spending by more than 20% year over year.
  • Genesis ended its first full quarter with $2 million in ARR. Inseyets conversions rose from nearly 65% of the install base at Q2-end to 75% at Q3-end.
  • Advanced unlocks doubled customers versus Q2, with strong sequential ARR growth; defense and intelligence continued growing in the mid-20s.
  • Management said it plans to introduce an on-premise AI version of Genesis before year-end and expects to deliver updated mobile-forensics capabilities and next-generation hardware before year-end.
This summary was generated by AI from the official earnings call transcript and is provided for informational purposes only. It does not constitute financial advice. For the complete transcript and financial data, visit CLBT on AllInvestView.

Get the Full Picture on CLBT

Track Cellebrite DI Ltd. Ordinary Shares in your portfolio with real-time analytics, dividend tracking, and more.

View CLBT Analysis